![[Toyota Times] Century as a Brand, Lexus as Innovation: All the Details on Toyota's New Project!](https://businessfortnight.com/wp-content/uploads/2025/10/Toyota-Times-Century-as-a-Brand-Lexus-as-Innovation-All-218x150.jpg "[Toyota Times] Century as a Brand, Lexus as Innovation: All the Details on Toyota's New Project!")
Beijing, China:
Sinovac Biotech Ltd. (“SINOVAC” or the “Company”) (NASDAQ: SVA), a number one supplier of biopharmaceutical merchandise in China, introduced that the Company will take part in CPHI Frankfurt, one of many world’s largest pharmaceutical exhibitions, from 1st to 3rd of November, in Frankfurt, Germany.
At Booth#41G20, the primary flooring of Hall 4, Messe Frankfurt, SINOVAC will greet all guests of CPHI and current its complete portfolio. The Company will showcase the one inactivated COVID-19 vaccine authorized for kids as younger as 6-months previous, CoronaVac®; the quadrivalent influenza vaccine, QIV; the world-leading enterovirus kind 71 vaccine, Inlive®; the varicella vaccine which supplies 100% safety in opposition to reasonable and extreme circumstances; and two WHO prequalified vaccines: the hepatitis A vaccine, Healive® and the Sabin-strain inactivated polio vaccine.
Helen Yang, Chief Business Officer of SINOVAC stated, “SINOVAC is an old friend of CPHI, and we are happy to finally return to CPHI’s in-person event for the first time since the outbreak of the COVID-19 pandemic globally. As always, we highly value the platform’s business potential, and plan to showcase many of our best products, especially those approved by the WHO and distributed to many countries around the world. We are eager to introduce our recent cutting-edge technologies to our global partners and to develop more business opportunities.”
To meet SINOVAC on web site, you might be welcome to go to Booth#41G20, or contact Alice Chen through [email protected] to schedule appointments.
About SINOVAC
Sinovac Biotech Ltd., (SINOVAC) is a China-based biopharmaceutical firm that focuses on the R&D, manufacturing, and commercialization of vaccines that defend in opposition to human infectious ailments.
SINOVAC’s product portfolio contains vaccines in opposition to COVID-19, enterovirus 71 (EV71) contaminated Hand-Foot-Mouth illness (HFMD), hepatitis A, seasonal influenza, pneumococcal illness, H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu), varicella, mumps, poliomyelitis, and many others.
The COVID-19 vaccine, CoronaVac®, has been authorized to be used in additional than 60 international locations and areas worldwide. The hepatitis A vaccine, Healive®, handed WHO prequalification necessities in 2017. The EV71 vaccine, Inlive®, is an revolutionary vaccine commercialized in China in 2016. In 2022, SINOVAC’s Sabin-strain inactivated polio vaccine (sIPV) was prequalified by the WHO.
SINOVAC was the primary firm to be granted approval for its H1N1 influenza vaccine Panflu.1®, which has provided the Chinese authorities’s vaccination marketing campaign and stockpiling program. The Company can be the one provider of the H5N1 pandemic influenza vaccine, Panflu®, to the Chinese authorities stockpiling program.
SINOVAC frequently dedicates itself to new vaccine R&D, with extra mixture vaccine merchandise in its pipeline, and continually explores international market alternatives. SINOVAC plans to conduct extra in depth and in-depth commerce and cooperation with further international locations, and business and business organizations.
For extra data, please see the Company’s web site at www.sinovac.com.
View supply model on businesswire.com: https://www.businesswire.com/news/home/20221028005130/en/
